Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$22.90 USD
-0.60 (-2.55%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $22.90 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STOK 22.90 -0.60(-2.55%)
Will STOK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Other News for STOK
1,2,3 Pullback Bullish appears for STOK after 3.34% move
The technical outlook for STOK is unchanged after it falls 1.81% on September 18
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
STOK forms Boomer Buy Setup on September 16
STOK forms Upper Bollinger Band Walk on September 15